Review



rabbit (rb) anti-zikv ns5  (GeneTex)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GeneTex rabbit (rb) anti-zikv ns5
    (A) Heatmap of normalized RNA-seq Z-score data for mock versus ZIKV-infected (left) and DENV-infected (right) Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock, ZIKV-, and DENV-infected Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV <t>NS5</t> (red), and DAPI (blue).
    Rabbit (Rb) Anti Zikv Ns5, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+(rb)+anti-zikv+ns5/anti+zikv+ns3+gtx133309/bio_rxiv__2024__10__18__619084-247-60-65
    Average 90 stars, based on 1 article reviews
    rabbit (rb) anti-zikv ns5 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence"

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence

    Journal: bioRxiv

    doi: 10.1101/2024.10.18.619084

    (A) Heatmap of normalized RNA-seq Z-score data for mock versus ZIKV-infected (left) and DENV-infected (right) Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock, ZIKV-, and DENV-infected Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).
    Figure Legend Snippet: (A) Heatmap of normalized RNA-seq Z-score data for mock versus ZIKV-infected (left) and DENV-infected (right) Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock, ZIKV-, and DENV-infected Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).

    Techniques Used: RNA Sequencing Assay, Infection, Comparison, Western Blot, Immunocytochemistry, Staining

    (A) Heatmap of NPC pathway-associated normalized RNA-seq transcripts for mock versus ZIKV-infected SK-N-SH samples at 1-, 3-, and 5-DPI. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock and ZIKV-infected SK-N-SH samples at 1-, 3-, 5-DPI. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV-infected sample. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).
    Figure Legend Snippet: (A) Heatmap of NPC pathway-associated normalized RNA-seq transcripts for mock versus ZIKV-infected SK-N-SH samples at 1-, 3-, and 5-DPI. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock and ZIKV-infected SK-N-SH samples at 1-, 3-, 5-DPI. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV-infected sample. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).

    Techniques Used: RNA Sequencing Assay, Infection, Comparison, Western Blot, Immunocytochemistry, Staining

    (A) Top panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. (B) Top panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Two images were counted for each antibody per sample and values were averaged. Error bars represent SEM.
    Figure Legend Snippet: (A) Top panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. (B) Top panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Two images were counted for each antibody per sample and values were averaged. Error bars represent SEM.

    Techniques Used: Immunocytochemistry, Infection

    Related Articles

    RNA Sequencing Assay:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).

    Infection:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).

    Comparison:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).

    Western Blot:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).

    Immunocytochemistry:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).

    Staining:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).

    Blocking Assay:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).

    Incubation:

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence
    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Article Title: Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity
    Article Snippet: After a blocking step with a 4% BSA solution, membranes were 424 incubated with the following primary antibodies at 4°C overnight: rb-a-IRF3 S386 1:500 425 (ab76493, abcam, MA, USA), rb-a-IRF3 S396 1:1000 (#29047, Cell Signaling Technology (CST), 426 Danvers, MA, USA), rb-a-IRF3 1:1000 (#4302, CST), rb-a-IFIT1 #971 1:1000 and rb-a-MxA #340B 427 1:500 (both made at UT Southwestern Antibody Core facility by repeated injections of synthetic 428 peptides into rabbits), m-a-pan-Actin C4 1:3000 (MAB1501, Millipore), rb-a-ZIKV-NS5 1:2500 429 (GTX133312, GeneTex, Irvine, CA, USA), goat-a-WNV-NS3 1:1000 (BAF2901, R&D systems, 430 Minneapolis, MN, USA), goat-a-Parainfluenza 1 (B65121G-1, amsbio, Cambridge, MA, USA), m-a-431 RIG-I AlmeI 1:1000 (AG-20B-0009-C100, AdipoGen, San Diego, CA, USA), rb-a-MDA5 1:500 432 (29020, IBL, Minneapolis, MN, USA), rb-a-LGP2 1:500 (29030, IBL), rb-a-Cardif AT107 1:1000 433 (ALX-210-929-C100, Enzo Life Sciences, Farmingdale, NY, USA).



    Similar Products

    rabbit (rb) anti-zikv ns5  (GeneTex)
    90
    GeneTex rabbit (rb) anti-zikv ns5
    (A) Heatmap of normalized RNA-seq Z-score data for mock versus ZIKV-infected (left) and DENV-infected (right) Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock, ZIKV-, and DENV-infected Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV <t>NS5</t> (red), and DAPI (blue).
    Rabbit (Rb) Anti Zikv Ns5, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+(rb)+anti-zikv+ns5/anti+zikv+ns3+gtx133309/bio_rxiv__2024__10__18__619084-247-60-65
    Average 90 stars, based on 1 article reviews
    rabbit (rb) anti-zikv ns5 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Heatmap of normalized RNA-seq Z-score data for mock versus ZIKV-infected (left) and DENV-infected (right) Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock, ZIKV-, and DENV-infected Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).

    Journal: bioRxiv

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence

    doi: 10.1101/2024.10.18.619084

    Figure Lengend Snippet: (A) Heatmap of normalized RNA-seq Z-score data for mock versus ZIKV-infected (left) and DENV-infected (right) Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock, ZIKV-, and DENV-infected Vero samples at 1-, 3-, 5-DPI, and long-term infected samples. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).

    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Techniques: RNA Sequencing Assay, Infection, Comparison, Western Blot, Immunocytochemistry, Staining

    (A) Heatmap of NPC pathway-associated normalized RNA-seq transcripts for mock versus ZIKV-infected SK-N-SH samples at 1-, 3-, and 5-DPI. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock and ZIKV-infected SK-N-SH samples at 1-, 3-, 5-DPI. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV-infected sample. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).

    Journal: bioRxiv

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence

    doi: 10.1101/2024.10.18.619084

    Figure Lengend Snippet: (A) Heatmap of NPC pathway-associated normalized RNA-seq transcripts for mock versus ZIKV-infected SK-N-SH samples at 1-, 3-, and 5-DPI. (B) A comparison of normalized RNA-seq reads represented in reads per million for NXT1 and visualized in IGV. Comparisons shown for mock and ZIKV-infected SK-N-SH samples at 1-, 3-, 5-DPI. (C) Western blot analysis of anti-NXT1 for mock, ZIKV-, and DENV-infected samples at 1-, 3-, 5-DPI as well as long-term DENV-infected sample. (D) Immunocytochemistry staining of mock, ZIKV, and DENV at 1- and 5-DPI. Antibodies used were anti-NXT1 (green), anti-ZIKV NS5 (red), and DAPI (blue).

    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Techniques: RNA Sequencing Assay, Infection, Comparison, Western Blot, Immunocytochemistry, Staining

    (A) Top panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. (B) Top panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Two images were counted for each antibody per sample and values were averaged. Error bars represent SEM.

    Journal: bioRxiv

    Article Title: Zika and Dengue Viruses Differentially Modulate Host mRNA Processing Factors Defining Its Virulence

    doi: 10.1101/2024.10.18.619084

    Figure Lengend Snippet: (A) Top panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated Vero samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. (B) Top panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-UPF1 (in green), anti-4G2 (in red), and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Bottom panel-Immunocytochemistry of LMB-treated and untreated SK-N-SH samples at 48 hours. Antibodies used were anti-NS5 (in green) and DAPI (in blue). Shown on the right is a graphical representation of the percentage of infected cells at each time point for treated and untreated samples. Two images were counted for each antibody per sample and values were averaged. Error bars represent SEM.

    Article Snippet: Primary antibodies used were as follows: Mouse (M) anti-4G2 (Cat# Ab00230-2.0, Absolute Antibody), M anti-DENV NS1 (Type 2/3/4) (Cat# MAB94441-100, R&D Systems), M anti-NXT1 (Cat#67680-1-Ig, Proteintech), M anti-alpha tubulin (Cat#66031-1-Ig, Proteintech), Rabbit (Rb) anti-beta actin (Cat# 026-42210, Li-cor), Rb anti-DENV NS5 (Cat#NBP2-42901, Novus Biologicals), Rb anti-GAPDH (Cat# 5174S, Cell Signaling Technology (CST)), Rb anti-UPF1 (Cat#12040, CST) Rb anti-UPF2 (Cat#11875, CST), Rb anti-ZIKV NS5 (Cat# GTX133312, GeneTex), Rb anti-ZIKV envelope (Cat# GTX133314, GeneTex).

    Techniques: Immunocytochemistry, Infection